Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Cambrian BioPharma
United States
- New York, New York
- 26/10/2021
- Series C
- $100,000,000
Cambrian BioPharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.
As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
- Industry Biotechnology Research
- Website https://www.cambrianbio.com/
- LinkedIn https://www.linkedin.com/company/cambrianbio/about/
Related People
James Peyer, PhDFounder
United States -
New York City Metropolitan Area
As Founder and CEO of Cambrian Bio, a Distributed Drug Development Company (or a "DisCo" as we like to call it), I’m focused on developing therapeutics targeting the biological drivers of aging. Cambrian builds, directs, operates, and finances a pipeline of therapeutics. I founded the company to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, because the world is entering a revolution in medical research that will change our relationship with medicines from REactive to PROactive. Learn more: www.cambrianbio.com
Before Cambrian, I started Apollo Ventures, the first company builder in Longevity Therapeutics, where I was founder, investor, and CEO of multiple companies. I did my PhD with a focus on blood stem cell biology as a National Science Foundation Fellow at UT Southwestern.
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)